AKBA:NSD-Akebia Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.60

Change

+0.13 (+5.26)%

Market Cap

USD 0.40B

Volume

1.79M

Avg Analyst Target

USD 7.00 (+169.23%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-6.99 (-1.98%)

USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.86 (+3.61%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+2.52 (+0.44%)

USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-3.26 (-1.62%)

USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.12 (+0.27%)

USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+10.83 (+3.42%)

USD29.25B N/A N/A
SGEN Seagen Inc

+0.85 (+0.55%)

USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

-0.99 (-2.59%)

USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

-0.98 (-0.55%)

USD21.03B N/A N/A

ETFs Containing AKBA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.14% 57% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.14% 57% F 26% F
Trailing 12 Months  
Capital Gain -77.57% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.57% 3% F 1% F
Trailing 5 Years  
Capital Gain -70.75% 26% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.75% 26% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain -3.19% 28% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.19% 27% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 70.78% 44% F 25% F
Risk Adjusted Return -4.51% 29% F 18% F
Market Capitalization 0.40B 56% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.85 77% C+ 64% D
Price / Cash Flow Ratio -3.58 29% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -128.57% 18% F 17% F
Return on Invested Capital -91.97% 21% F 8% F
Return on Assets -14.83% 73% C 23% F
Debt to Equity Ratio 39.90% 29% F 44% F
Technical Ratios  
Short Ratio 4.19 45% F 31% F
Short Percent 9.91% 30% F 19% F
Beta 1.74 30% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector